Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755726 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 | |
| SCHEMBL19841251 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 | |
| SCHEMBL18025232 | 0.78 | — | — | |
| SCHEMBL21547596 | 0.77 | — | — | |
| SCHEMBL25588698 | 0.77 | ALDH1A1 (0.38) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 | |
| SCHEMBL19882464 | 0.77 | CYP2D6 (0.38) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 | |
| SCHEMBL18135504 | 0.77 | — | — | |
| SCHEMBL23057467 | 0.75 | PIK3CD (0.39) | — | |
| SCHEMBL24952291 | 0.75 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 | |
| SCHEMBL22843 | 0.75 | ALDH1A1 (0.36) | ALDH1A1CYP2D6CYP2C19HSD17B10SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | UNIV ZHEJIANG (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284625-A1 | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | CHEK1, PLK1, CHEK2 | ALDH1A1 3029/4885CYP2D6 1887/4885CYP2C19 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.